Corrigendum to “TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain” [Biochem. Pharmacol. 192 (2021) 114688]

The authors of this paper would like to point out that the ‘Declaration of Competing Interest’ statement omitted the following text:

“David Tweardy receives compensation as a member of Tvardi Therapeutics’ scientific advisory board and also holds equity in the company.”

The authors apologise for this error.